Literature DB >> 29779027

Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes.

Carola-Ellen Kleine1,2, Melissa Soohoo1,2,3, Omesh N Ranasinghe1, Christina Park1,2, Maria V Marroquin1,2, Yoshitsugu Obi1, Connie M Rhee1, Hamid Moradi1,2, Csaba P Kovesdy4,5, Kamyar Kalantar-Zadeh1,2,3, Elani Streja1,2.   

Abstract

BACKGROUND: Incident hemodialysis patients have a high mortality risk within the first months after dialysis initiation. Pre-end-stage renal disease (ESRD) factors like anemia management may impact early post-ESRD outcomes. Therefore, we evaluated the impact of pre-ESRD hemoglobin (Hgb) and pre-ESRD Hgb slope on post-ESRD mortality and hospitalization outcomes.
METHODS: The study included 31,472 veterans transitioning to ESRD. Using Cox and negative binomial regression models, we evaluated the association of pre-ESRD Hgb and Hgb slope with 12-month post-ESRD all-cause and cardiovascular mortality and hospitalization rates using 4 levels of hierarchical multivariable adjustment, including erythropoietin use and kidney decline in slope models.
RESULTS: The cohort was 2% female, 30% African-American, and on average 68 ± 11 years old. Compared to Hgb 10-< 11 g/dL, both low (< 10 g/dL) and high (≥12 g/dL) levels were associated with higher all-cause mortality after full adjustment (HR 1.25 [95% CI 1.15-1.35] and 1.09 [95% CI 1.02-1.18], respectively). Similarly, Hgb exhibited a U-shaped association with CV mortality, while only lower Hgb was associated with a higher hospitalization rate. Neither an annual pre-ESRD decline in Hgb nor increase was associated with higher post-ESRD mortality risk after adjustment for kidney decline. However, we observed a modest J-shaped association between pre-ESRD Hgb slope and post-ESRD hospitalization rate.
CONCLUSIONS: Lower and higher pre-ESRD Hgb levels are associated with a higher risk of early post-ESRD mortality, while there was no association between the pre-ESRD slope and mortality. An increase in pre-ESRD Hgb slope was associated with higher risk of post-ESRD hospitalization. Additional studies aimed at anemia management prior to ESRD transition are warranted.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Anemia; Chronic kidney disease; End-stage renal disease; Hemoglobin; Mortality

Mesh:

Substances:

Year:  2018        PMID: 29779027     DOI: 10.1159/000489223

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  5 in total

1.  A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.

Authors:  Geoffrey A Block; Martha S Block; Gerard Smits; Rupal Mehta; Tamara Isakova; Myles Wolf; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2019-07-05       Impact factor: 10.121

2.  Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD.

Authors:  Ekamol Tantisattamo; Victoria Murray; Yoshitsugu Obi; Christina Park; Christina J Catabay; Yuji Lee; Cachet Wenziger; Jui-Ting Hsiung; Melissa Soohoo; Carola-Ellen Kleine; Connie M Rhee; Jeffrey Kraut; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Elani Streja
Journal:  Am J Nephrol       Date:  2021-04-23       Impact factor: 3.754

Review 3.  Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.

Authors:  Norishi Ueda; Kazuya Takasawa
Journal:  Nutrients       Date:  2018-08-27       Impact factor: 5.717

4.  Hidden Hypocalcemia as a Risk Factor for Cardiovascular Events and All-Cause Mortality among Patients Undergoing Incident Hemodialysis.

Authors:  Satoshi Yamaguchi; Takayuki Hamano; Yohei Doi; Tatsufumi Oka; Sachio Kajimoto; Keiichi Kubota; Seiichi Yasuda; Karin Shimada; Ayumi Matsumoto; Nobuhiro Hashimoto; Yusuke Sakaguchi; Isao Matsui; Yoshitaka Isaka
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

5.  Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study.

Authors:  Yang Xu; Marie Evans; Peter Barany; Glen James; Arvid Sjölander; Juan Jesus Carrero
Journal:  Clin Kidney J       Date:  2021-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.